Vanda Pharmaceuticals held a conference call Conference call to discuss positive Phase III results for Tasimelteon for the treatment of a non-24 hour disorder was held on December 18 at 9 am and has a replay available from 11 am on December 18 through December 25. Webcast Link
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Vanda pullback a buying opportunity, says Piper Jaffray Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.